Phase 2 Randomized Bivalent RSVpreF Maternal Vaccine Trial: Final Safety, Antibody Persistence and Efficacy

Clicks: 6
ID: 322588
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #231 of 430 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 430 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: This report summarizes the final results from a randomized, placebo-controlled, phase 2b trial evaluating safety, antibody persistence, and potential efficacy of a bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine in pregnant individuals and their infants. METHODS: Maternal participants were randomized from 24-36 weeks gestation to receive RSVpreF (120 or 240 µg ± aluminum hydroxide) or placebo. RESULTS: This analysis included 579 pregnant individuals and 572 infants from 4 countries (Argentina, Chile, South Africa, United States); 462 maternal participants received RSVpreF. Adverse events in the month following vaccination (maternal) or birth (infant) were mostly anticipated events in pregnancy and the neonatal period, respectively. For all RSVpreF groups, combined RSV-A/-B 50% neutralizing titers peaked 2 weeks after vaccination. At delivery, geometric mean titer ratios between RSVpreF and placebo recipients' infants were 10.9-13.6. Transplacental transfer ratios (all groups) were 1.39-1.83. Neutralizing geometric mean titers remained higher in infants whose mothers received RSVpreF versus placebo through their first 6 months of life, with an estimated half-life of 39-44 days. In an exploratory analysis, observed efficacy (95% confidence interval) for the combined RSVpreF groups against medically attended and severe medically attended infant RSV lower respiratory tract illness through the first 180 days of life was 75% (-11%, 94%) and 83% (-48%, 99%), respectively. CONCLUSIONS: RSVpreF had a favorable safety profile and elicited robust neutralizing responses with efficient transplacental transfer. The potential to prevent infant RSV-associated lower respiratory tract illness was subsequently confirmed in the pivotal phase 3 efficacy trial. (NCT04032093).
Reference Key
openalex_W7170189950 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eric A F Simões, Shabir A. Madhi, Alan Tita, Conrado Llapur, José M Novoa P, Kena A Swanson, David Radley, Emily Gomme, Linda G Brock, Daniel A. Scott, Iona Munjal, Stephanie McGrory, Annaliesa S. Anderson, William C. Gruber, Alejandra Gurtman
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag378
URL
https://doi.org/10.1093/infdis/jiag378
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.